JULIA LEIBOLD,PHILLIP MLLER,HARPREET SINGH,JENS FRITSCHE,OLIVER SCHOOR,TONI WEINSCHENK,ANDREA MAHR,VALENTINA GOLDFINGER
申请号：
ARP160102395
公开号：
AR105817A1
申请日:
2016.08.04
申请国别(地区):
AR
年份:
2017
代理人:
摘要：
Requirement 1: peptide, including amino acid sequence selected from the group of SEQ No. 1 to SEQ No. 48, and at least 88% alternative sequence selected from the group of SEQ No. 1 to SEQ No. 48, And the variant cross reacts with one or more molecules in the larger histocompatibility complex and / or induces T lymphocytes to cross react with the variant； and a pharmaceutically acceptable salt, wherein the peptide is not a complete peptide. Claim 7: nucleic acid, encoded according to any peptide or variant thereof consistent with claims 1 to 6,You can choose to link to the Hetrologa promotion program. Claim 12: a test tube method for producing activated T lymphocytes, 2.1.2.1.1.2. The method is to contact the T-lymphocyte in the test tube containing one or two kinds of human MHC molecules with the serum, which is displayed on the surface of the appropriate antigen display cell, or simulate the antigen display cell in an artificial structure for a long time Activate these T lymphocytes in a specific antigen wayAn antigen is a peptide that meets any of the requirements of items 1 to 4 Claim 14: a method for destroying the target cell of a patient whose target cell is a polypeptide, the polypeptide comprising a series of amino acids as defined in any one of claims 1 to 4, This method includes injecting an effective number of active T-lymphocytes into the patient's body, as defined in claim 13. Claim 18: includes (a) a container containing pharmaceutical ingredients containing peptides or their substitutes in accordance with any claims 1 to 6,a. Nucleic acids in accordance with item 7, expression vectors in accordance with item 8, cells in accordance with item 10, active T-lymphocytes in accordance with item 13 or antibodies in accordance with item 15, in the form of dissolution or dissolution； (b) The second optional package contains diluent or solution prepared by liofilizada； (c) optional, at least one more selective combined peptide from SEQ ID No.1 to SEQ ID NO.1159
